OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States.

The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.

The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets.

The company was founded in 2012 and is headquartered in Emeryville, California.